Myc induced replicative stress response: How to cope with it and exploit it

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1849, Issue 5, 2015, Pages 517-524

  Rohban, Sara ^a   Campaner, Stefano ^a  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

ATR; Chk1; DNA replication; Myc; Replicative stress

Indexed keywords

ATAXIA TELANGIECTASIA MUTATED PROTEINS; ATR PROTEIN, HUMAN; CHECKPOINT KINASE 1; MYC PROTEIN, HUMAN; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-MYC;

BIOSYNTHESIS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETICS; HUMANS; NEOPLASMS; PATHOLOGY;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84899035081     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.04.008     Document Type: Review

References (145)

1. Shen-Ong G.L., Keath E.J., Piccoli S.P., Cole M.D. Novel Myc oncogene RNA from abortive immunoglobulin-gene recombination in mouse plasmacytomas. Cell 1982, 31:443-452.
2. Crews S., Barth R., Hood L., Prehn J., Calame K. Mouse c-Myc oncogene is located on chromosome 15 and translocated to chromosome 12 in plasmacytomas. Science 1982, 218:1319-1321.
3. Dalla-Favera R., Bregni M., Erikson J., Patterson D., Gallo R.C., Croce C.M. Human c-Myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:7824-7827.
4. Neel B.G., Jhanwar S.C., Chaganti R.S., Hayward W.S. Two human c-onc genes are located on the long arm of chromosome 8. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:7842-7846.
5. Taub R., Kirsch I., Morton C., Lenoir G., Swan D., Tronick S., et al. Translocation of the c-Myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:7837-7841.
6. Dalla-Favera R., Wong-Staal F., Gallo R.C. Onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient. Nature 1982, 299:61-63.
7. Collins S., Groudine M. Amplification of endogenous Myc-related DNA sequences in a human myeloid leukaemia cell line. Nature 1982, 298:679-681.
8. Payne G.S., Courtneidge S.A., Crittenden L.B., Fadly A.M., Bishop J.M., Varmus H.E. Analysis of avian leukosis virus DNA and RNA in bursal tumours: viral gene expression is not required for maintenance of the tumor state. Cell 1981, 23:311-322.
9. Hayward W.S., Neel B.G., Astrin S.M. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 1981, 290:475-480.
10. Hemann M.T., Bric A., Teruya-Feldstein J., Herbst A., Nilsson J.A., Cordon-Cardo C., et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005, 436:807-811.
11. Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W., Zhang M., et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490:116-120.
12. Sur I., Tuupanen S., Whitington T., Aaltonen L.A., Taipale J. Lessons from functional analysis of genome-wide association studies. Cancer Res. 2013, 73:4180-4184.
13. Murre C., McCaw P.S., Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and Myc proteins. Cell 1989, 56:777-783.
14. Landschulz W.H., Johnson P.F., McKnight S.L. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 1988, 240:1759-1764.
15. Blackwood E.M., Eisenman R.N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991, 251:1211-1217.
16. Amati B., Dalton S., Brooks M.W., Littlewood T.D., Evan G.I., Land H. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 1992, 359:423-426.
17. Stone J., de Lange T., Ramsay G., Jakobovits E., Bishop J.M., Varmus H., et al. Definition of regions in human c-Myc that are involved in transformation and nuclear localization. Mol. Cell. Biol. 1987, 7:1697-1709.
18. Li L.H., Nerlov C., Prendergast G., MacGregor D., Ziff E.B. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. Embo J. 1994, 13:4070-4079.
19. Mao D.Y.L., Watson J.D., Yan P.S., Barsyte-Lovejoy D., Khosravi F., Wong W.W.-L., et al. Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curbio 2003, 13:882-886.
20. Kleine-Kohlbrecher D., Adhikary S., Eilers M. Mechanisms of transcriptional repression by Myc. Curr. Top. Microbiol. Immunol. 2006, 302:51-62.
21. Perna D., Faga G., Verrecchia A., Gorski M.M., Barozzi I., Narang V., et al. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene 2012, 31:1695-1709.
22. Lin C.Y., Lovén J., Rahl P.B., Paranal R.M., Burge C.B., Bradner J.E., et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012, 151:56-67.
23. Nie Z., Hu G., Wei G., Cui K., Yamane A., Resch W., et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012, 151:68-79.
24. Seitz V., Butzhammer P., Hirsch B., Hecht J., Gütgemann I., Ehlers A., et al. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. PLoS ONE 2011, 6:e26837.
25. Nishitani H., Lygerou Z. DNA replication licensing. Front. Biosci. 2004, 9:2115-2132.
26. Blow J.J., Dutta A. Preventing re-replication of chromosomal DNA. Nat. Rev. Mol. Cell Biol. 2005, 6:476-486.
27. Costa A., Ilves I., Tamberg N., Petojevic T., Nogales E., Botchan M.R., et al. The structural basis for MCM2-7 helicase activation by GINS and Cdc45. Nat. Struct. Mol. Biol. 2011, 18:471-477.
28. Remus D., Diffley J.F.X. Eukaryotic DNA replication control: lock and load, then fire. Curr. Opin. Cell Biol. 2009, 21:771-777.
29. Fu Y.V., Yardimci H., Long D.T., Ho T.V., Guainazzi A., Bermudez V.P., et al. Selective bypass of a lagging strand roadblock by the eukaryotic replicative DNA helicase. Cell 2011, 146:931-941.
30. Gambus A., Jones R.C., Sanchez-Diaz A., Kanemaki M., van Deursen F., Edmondson R.D., et al. GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks. Nat. Cell Biol. 2006, 8:358-366.
31. Ilves I., Petojevic T., Pesavento J.J., Botchan M.R. Activation of the MCM2-7 helicase by association with Cdc45 and GINS proteins. Mol. Cell 2010, 37:247-258.
32. Pacek M., Tutter A.V., Kubota Y., Takisawa H., Walter J.C. Localization of MCM2-7, Cdc45, and GINS to the site of DNA unwinding during eukaryotic DNA replication. Mol. Cell 2006, 21:581-587.
33. Heller R.C., Kang S., Lam W.M., Chen S., Chan C.S., Bell S.P. Eukaryotic origin-dependent DNA replication in vitro reveals sequential action of DDK and S-CDK kinases. Cell 2011, 146:80-91.
34. Labib K. How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells?. Genes Dev. 2010, 24:1208-1219.
35. Mimura S., Takisawa H. Xenopus Cdc45-dependent loading of DNA polymerase alpha onto chromatin under the control of S-phase Cdk. Embo J. 1998, 17:5699-5707.
36. Blow J.J., Gillespie P.J. Replication licensing and cancer-a fatal entanglement?. Nat. Rev. Cancer 2008, 8:799-806.
37. Lei M., Kawasaki Y., Tye B.K. Physical interactions among Mcm proteins and effects of Mcm dosage on DNA replication in Saccharomyces cerevisiae. Mol. Cell. Biol. 1996, 16:5081-5090.
38. Mahbubani H.M., Chong J.P., Chevalier S., Thommes P., Blow J.J. Cell cycle regulation of the replication licensing system: involvement of a Cdk-dependent inhibitor. J. Cell Biol. 1997, 136:125-135.
39. Edwards M.C., Tutter A.V., Cvetic C., Gilbert C.H., Prokhorova T.A., Walter J.C. MCM2-7 complexes bind chromatin in a distributed pattern surrounding the origin recognition complex in Xenopus egg extracts. J. Biol. Chem. 2002, 277:33049-33057.
40. Oehlmann M., Score A.J., Blow J.J. The role of Cdc6 in ensuring complete genome licensing and S phase checkpoint activation. J. Cell Biol. 2004, 165:181-190.
41. Ge X.Q., Jackson D.A., Blow J.J. Dormant origins licensed by excess Mcm2-7 are required for human cells to survive replicative stress. Genes Dev. 2007, 21:3331-3341.
42. Ibarra A., Schwob E., Mendez J. Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8956-8961.
43. Woodward A.M., Gohler T., Luciani M.G., Oehlmann M., Ge X., Gartner A., et al. Excess Mcm2-7 license dormant origins of replication that can be used under conditions of replicative stress. J. Cell Biol. 2006, 173:673-683.
44. Kelly K., Cochran B.H., Stiles C.D., Leder P. Cell-specific regulation of the c-Myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 1983, 35:603-610.
45. Thompson C.B., Challoner P.B., Neiman P.E., Groudine M. Levels of c-Myc oncogene mRNA are invariant throughout the cell cycle. Nature 1985, 314:363-366.
46. Gonda T.J., Metcalf D. Expression of Myb, Myc and Fos proto-oncogenes during the differentiation of a murine myeloid leukaemia. Nature 1984, 310:249-251.
47. Lachman H.M., Skoultchi A.I. Expression of c-Myc changes during differentiation of mouse erythroleukaemia cells. Nature 1984, 310:592-594.
48. Armelin H.A., Armelin M.C., Kelly K., Stewart T., Leder P., Cochran B.H., et al. Functional role for c-Myc in mitogenic response to platelet-derived growth factor. Nature 1984, 310:655-660.
49. Eilers M., Picard D., Yamamoto K.R., Bishop J.M. Chimaeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature 1989, 340:66-68.
50. Eilers M., Schirm S., Bishop J.M. The MYC protein activates transcription of the alpha-prothymosin gene. Embo J. 1991, 10:133-141.
51. Pelengaris S., Littlewood T., Khan M., Elia G., Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 1999, 3:565-577.
52. Pelengaris S., Khan M., Evan G.I. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002, 109:321-334.
53. Grandori C., Wu K.-J., Fernandez P., Ngouenet C., Grim J., Clurman B.E., et al. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev. 2003, 17:1569-1574.
54. Robinson K., Asawachaicharn N., Galloway D.A., Grandori C. c-Myc accelerates S-phase and requires WRN to avoid replication stress. PLoS ONE 2009, 4:e5951.
55. Srinivasan S.V., Dominguez-Sola D., Wang L.C., Hyrien O., Gautier J. Cdc45 is a critical effector of Myc-dependent DNA replication stress. Cell Rep. 2013, 3:1629-1639.
56. Amati B., Alevizopoulos K., Vlach J. Myc and the cell cycle. Front. Biosci. 1998, 3:d250-d268.
57. Fernandez P.C., Frank S.R., Wang L., Schroeder M., Liu S., Greene J., et al. Genomic targets of the human c-Myc protein. Genes Dev. 2003, 17:1115-1129.
58. Bouchard C., Thieke K., Maier A., Saffrich R., Hanley-Hyde J., Ansorge W., et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. Embo J. 1999, 18:5321-5333.
59. Menssen A., Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6274-6279.
60. Hermeking H., Rago C., Schuhmacher M., Li Q., Barrett J.F., Obaya A.J., et al. Identification of CDK4 as a target of c-MYC. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2229-2234.
61. Miliani de Marval P.L., Macias E., Rounbehler R., Sicinski P., Kiyokawa H., Johnson D.G., et al. Lack of cyclin-dependent kinase 4 inhibits c-Myc tumorigenic activities in epithelial tissues. Mol. Cell. Biol. 2004, 24:7538-7547.
62. Campaner S., Doni M., Hydbring P., Verrecchia A., Bianchi L., Sardella D., et al. Cdk2 suppresses cellular senescence induced by the c-Myc oncogene. Nat. Cell Biol. 2010, 12:54-59. (sup pp 1-14).
63. Kozar K., Ciemerych M.A., Rebel V.I., Shigematsu H., Zagozdzon A., Sicinska E., et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004, 118:477-491.
64. Claassen G.F., Hann S.R. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta-induced cell-cycle arrest. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:9498-9503.
65. Seoane J., Le H.-V., MassaguE J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002, 419:729-734.
66. Gartel A.L., Ye X., Goufman E., Shianov P., Hay N., Najmabadi F., et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4510-4515.
67. Staller P., Peukert K., Kiermaier A., Seoane J., Lukas J., Karsunky H., et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat. Cell Biol. 2001, 3:392-399.
68. Seoane J., Pouponnot C., Staller P., Schader M., Eilers M., Massague J. TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat. Cell Biol. 2001, 3:400-408.
69. Marhin W.W., Chen S., Facchini L.M., Fornace A.J.J., Penn L.Z. Myc represses the growth arrest gene gadd45. Oncogene 1997, 14:2825-2834.
70. Lee T.C., Li L., Philipson L., Ziff E.B. Myc represses transcription of the growth arrest gene gas1. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:12886-12891.
71. Perna D., Faga G., Verrecchia A., Gorski M.M., Barozzi I., Narang V., et al. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene 2012, 31:1695-1709.
72. Liu Y.-C., Li F., Handler J., Huang C.R.L., Xiang Y., Neretti N., et al. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS ONE 2008, 3:e2722.
73. Dominguez-Sola D., Ying C.Y., Grandori C., Ruggiero L., Chen B., Li M., et al. Non-transcriptional control of DNA replication by c-Myc. Nature 2007, 448:445-451.
74. Pusapati R.V., Rounbehler R.J., Hong S., Powers J.T., Yan M., Kiguchi K., et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1446-1451.
75. Reimann M., Loddenkemper C., Rudolph C., Schildhauer I., Teichmann B., Stein H., et al. The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood 2007, 110:2996-3004.
76. Gorrini C., Squatrito M., Luise C., Syed N., Perna D., Wark L., et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 2007, 448:1063-1067.
77. Felsher D.W., Bishop J.M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3940-3944.
78. Karlsson A., Deb-Basu D., Cherry A., Turner S., Ford J., Felsher D.W. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9974-9979.
79. Neiman P.E., Kimmel R., Icreverzi A., Elsaesser K., Bowers S.-J., Burnside J., et al. Genomic instability during Myc-induced lymphomagenesis in the bursa of Fabricius. Oncogene 2006, 25:6325-6335.
80. Prochownik E.V. c-Myc: linking transformation and genomic instability. Curr. Mol. Med. 2008, 8:446-458.
81. Ray S. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res. 2006, 66:6598-6605.
82. Kuzyk A., Mai S. c-MYC-induced genomic instability. Cold Spring Harb. Perspect. Med. 2014, 4.
83. Egler R.A., Fernandes E., Rothermund K., Sereika S., de Souza-Pinto N., Jaruga P., et al. Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene 2005, 24:8038-8050.
84. Graves J.A., Metukuri M., Scott D., Rothermund K., Prochownik E.V. Regulation of reactive oxygen species homeostasis by peroxiredoxins and c-Myc. J. Biol. Chem. 2009, 284:6520-6529.
85. Wonsey D.R., Zeller K.I., Dang C.V. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6649-6654.
86. Gao P., Zhang H., Dinavahi R., Li F., Xiang Y., Raman V., et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007, 12:230-238.
87. Zhang H., Gao P., Fukuda R., Kumar G., Krishnamachary B., Zeller K.I., et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cell 2007, 11:407-420.
88. Louis S.F., Vermolen B.J., Garini Y., Young I.T., Guffei A., Lichtensztejn Z., et al. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9613-9618.
89. Felsher D.W., Zetterberg A., Zhu J., Tlsty T., Bishop J.M. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:10544-10548.
90. Toledo L.I., Altmeyer M., Rask M.-B., Lukas C., Larsen D.H., Klitgaard Povlsen Lou, et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 2013, 155:1088-1103.
91. Skourti-Stathaki K., Proudfoot N.J., Gromak N. Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent termination. Mol. Cell 2011, 42:794-805.
92. Lin Y., Dent S.Y.R., Wilson J.H., Wells R.D., Napierala M. R loops stimulate genetic instability of CTG.CAG repeats. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:692-697.
93. Reddy K., Tam M., Bowater R.P., Barber M., Tomlinson M., Nichol Edamura K., et al. Determinants of R-loop formation at convergent bidirectionally transcribed trinucleotide repeats. Nucleic Acids Res. 2011, 39:1749-1762.
94. Helmrich A., Ballarino M., Nudler E., Tora L. Transcription-replication encounters, consequences and genomic instability. Nat. Struct. Mol. Biol. 2013, 20:412-418.
95. Mischo H.E., Gomez-Gonzalez B., Grzechnik P., Rondón A.G., Wei W., Steinmetz L., et al. Yeast Sen1 helicase protects the genome from transcription-associated instability. Mol. Cell 2011, 41:21-32.
96. Huertas P., Aguilera A. Cotranscriptionally formed DNA:RNA hybrids mediate transcription elongation impairment and transcription-associated recombination. Mol. Cell 2003, 12:711-721.
97. Dutta D., Shatalin K., Epshtein V., Gottesman M.E., Nudler E. Linking RNA polymerase backtracking to genome instability in E. coli. Cell 2011, 146:533-543.
98. Tuduri S., Crabbe L., Conti C., Tourriere H., Holtgreve-Grez H., Jauch A., et al. Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat. Cell Biol. 2009, 11:1315-1324.
99. Helmrich A., Ballarino M., Tora L. Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol. Cell 2011, 44:966-977.
100. Bermejo R., Lai M.S., Foiani M. Preventing replication stress to maintain genome stability: resolving conflicts between replication and transcription. Mol. Cell 2012, 45:710-718.
101. Beier R., Bürgin A., Kiermaier A., Fero M., Karsunky H., Saffrich R., et al. Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events. Embo J. 2000, 19:5813-5823.
102. Jones R.M., Mortusewicz O., Afzal I., Lorvellec M., Garcia P., Helleday T., et al. Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress. Oncogene 2013, 32:3744-3753.
103. Barlow J.H., Faryabi R.B., Callén E., Wong N., Malhowski A., Chen H.T., et al. Identification of early replicating fragile sites that contribute to genome instability. Cell 2013, 152:620-632.
104. Murga M., Campaner S., Lopez-Contreras A.J., Toledo L.I., Soria R., Montana M.F., et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat. Struct. Mol. Biol. 2011, 18:1331-1335.
105. Bartek J., Bartkova J., Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007, 26:7773-7779.
106. Durkin S.G., Glover T.W. Chromosome fragile sites. Annu. Rev. Genet. 2007, 41:169-192.
107. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
108. Gorgoulis V.G., Vassiliou L.-V.F., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
109. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
110. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
111. Shreeram S., Hee W.K., Demidov O.N., Kek C., Yamaguchi H., Fornace A.J.J., et al. Regulation of ATM/p53-dependent suppression of Myc-induced lymphomas by Wip1 phosphatase. J. Exp. Med. 2006, 203:2793-2799.
112. Maclean K.H., Kastan M.B., Cleveland J.L. Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis. Mol. Cancer Res. 2007, 5:705-711.
113. Campaner S., Amati B. Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance. Cell Div. 2012, 7:6.
114. Pichierri P., Ammazzalorso F., Bignami M., Franchitto A. The Werner syndrome protein: linking the replication checkpoint response to genome stability. Aging 2011, 3:311-318. (Albany NY).
115. Sidorova J.M., Li N., Folch A., Monnat R.J.J. The RecQ helicase WRN is required for normal replication fork progression after DNA damage or replication fork arrest. Cell Cycle 2008, 7:796-807.
116. Moser R., Toyoshima M., Robinson K., Gurley K.E., Howie H.L., Davison J., et al. MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency. Mol Cancer Res. 2012, 10:535-545.
117. Bester A.C., Roniger M., Oren Y.S., Im M.M., Sarni D., Chaoat M., et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 2011, 145:435-446.
118. Lopez-Contreras A.J., Fernandez-Capetillo O. The ATR barrier to replication-born DNA damage. DNA Repair (Amst) 2010, 9:1249-1255.
119. Brown E.J., Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev. 2003, 17:615-628.
120. de Klein A., Muijtjens M., van Os R., Verhoeven Y., Smit B., Carr A.M., et al. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curbio 2000, 10:479-482.
121. Takai H., Tominaga K., Motoyama N., Minamishima Y.A., Nagahama H., Tsukiyama T., et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev. 2000, 14:1439-1447.
122. Nam E.A., Cortez D. ATR signalling: more than meeting at the fork. Biochem. J. 2011, 436:527-536.
123. O'Driscoll M., Ruiz-Perez V.L., Woods C.G., Jeggo P.A., Goodship J.A. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat. Genet. 2003, 33:497-501.
124. Murga M., Bunting S., Montana M.F., Soria R., Mulero F., Canamero M., et al. A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat. Genet. 2009, 41:891-898.
125. Cimprich K.A., Cortez D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 2008, 9:616-627.
126. Hoglund A., Nilsson L.M., Muralidharan S.V., Hasvold L.A., Merta P., Rudelius M., et al. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin. Cancer Res. 2011, 17:7067-7079.
127. Schoppy D.W., Ragland R.L., Gilad O., Shastri N., Peters A.A., Murga M., et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J. Clin. Invest. 2012, 122:241-252.
128. Gilad O., Nabet B.Y., Ragland R.L., Schoppy D.W., Smith K.D., Durham A.C., et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 2010, 70:9693-9702.
129. Ferrao P.T., Bukczynska E.P., Johnstone R.W., McArthur G.A. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 2012, 31:1661-1672.
130. Cole K.A., Huggins J., Laquaglia M., Hulderman C.E., Russell M.R., Bosse K., et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proceedings of the National Academy of Sciences 2011, 108:3336-3341.
131. Lopez-Contreras A.J., Gutierrez-Martinez P., Specks J., Rodrigo-Perez S., Fernandez-Capetillo O. An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation. J. Exp. Med. 2012, 209:455-461.
132. Zhou Z., Elledge S.J. DUN1 encodes a protein kinase that controls the DNA damage response in yeast. Cell 1993, 75:1119-1127.
133. Huang M., Zhou Z., Elledge S.J. The DNA replication and damage checkpoint pathways induce transcription by inhibition of the Crt1 repressor. Cell 1998, 94:595-605.
134. Zhao X., Rothstein R. The Dun1 checkpoint kinase phosphorylates and regulates the ribonucleotide reductase inhibitor Sml1. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3746-3751.
135. Zhao X., Muller E.G., Rothstein R. A suppressor of two essential checkpoint genes identifies a novel protein that negatively affects dNTP pools. Mol. Cell 1998, 2:329-340.
136. Zhang Y.W., Jones T.L., Martin S.E., Caplen N.J., Pommier Y. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. J. Biol. Chem. 2009, 284:18085-18095.
137. D'Angiolella V., Donato V., Forrester F.M., Jeong Y.-T., Pellacani C., Kudo Y., et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell 2012, 149:1023-1034.
138. Naruyama H., Shimada M., Niida H., Zineldeen D.H., Hashimoto Y., Kohri K., et al. Essential role of Chk1 in S phase progression through regulation of RNR2 expression. Biochem. Biophys. Res. Commun. 2008, 374:79-83.
139. Aird K.M., Zhang G., Li H., Tu Z., Bitler B.G., Garipov A., et al. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep. 2013, 3:1252-1265.
140. Schoppy D.W., Ragland R.L., Gilad O., Shastri N., Peters A.A., Murga M., et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J. Clin. Invest. 2012, 122:241-252.
141. Choi H.J.C., Lin J.-R., Vannier J.-B., Slaats G.G., Kile A.C., Paulsen R.D., et al. NEK8 links the ATR-regulated replication stress response and S phase CDK activity to renal ciliopathies. Mol. Cell 2013, 51:423-439.
142. Burrell R.A., McClelland S.E., Endesfelder D., Groth P., Weller M.-C., Shaikh N., et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 2013, 494:492-496.
143. Fokas E., Yoshimura M., Prevo R., Higgins G., Hackl W., Maira S.-M., et al. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat. Oncol. 2012, 7:48.
144. Schonbrun M., Laor D., Lopez-Maury L., Bahler J., Kupiec M., Weisman R. TOR complex 2 controls gene silencing, telomere length maintenance, and survival under DNA-damaging conditions. Mol. Cell. Biol. 2009, 29:4584-4594.
145. Shimada K., Filipuzzi I., Stahl M., Helliwell S.B., Studer C., Hoepfner D., et al. Short article. Mol. Cell 2013, 51:829-839.